Esta página foi traduzida automaticamente e a precisão da tradução não é garantida. Por favor, consulte o versão em inglês para um texto fonte.

Correlation Between Carbapenemase-Producing Enterobacterales Load, Environmental Contamination, and Transmission in Critical Care Units (CPE-Load ICU S)

29 de junho de 2026 atualizado por: MARIA INES STANELONI, Hospital Italiano de Buenos Aires

Carbapenemase-producing Enterobacterales (CPE) are multidrug-resistant bacteria that can colonize the gastrointestinal tract of hospitalized patients and spread within intensive care units (ICUs). Some colonized individuals may carry a particularly high bacterial burden and contribute disproportionately to environmental contamination and transmission to other patients. Identifying these high-risk individuals could improve infection prevention and control strategies.

This prospective observational study will be conducted in the Adult Intensive Care Unit of Hospital Italiano de Buenos Aires. Patients identified as colonized with CPE through routine surveillance will undergo quantitative culture and real-time polymerase chain reaction (PCR) testing of rectal swabs to measure bacterial load. Environmental samples will also be collected from high-touch surfaces surrounding colonized patients. In selected cases, molecular typing methods will be used to evaluate genetic relatedness between patient and environmental isolates and to investigate possible transmission events.

The primary objective is to determine the correlation between bacterial load measured by culture and the PCR cycle threshold (Ct) value. Secondary objectives include evaluating the association between bacterial load and environmental contamination, and assessing whether patients with higher bacterial loads are more likely to contribute to transmission within the ICU. Results may help identify patients with increased dissemination potential and support targeted infection prevention interventions.

Visão geral do estudo

Descrição detalhada

Carbapenemase-producing Enterobacterales (CPE) represent a major global public health threat because of their extensive antimicrobial resistance and their ability to spread within healthcare facilities. Gastrointestinal colonization is recognized as the main reservoir for transmission. Previous studies have suggested that a subset of colonized patients, often referred to as "super-spreaders," carry a substantially higher bacterial burden and may account for a disproportionate share of environmental contamination and transmission events.

Although bacterial load can be quantified using culture-based and molecular methods, there is currently no validated cycle threshold (Ct) value from routinely used real-time PCR assays that reliably identifies patients with high dissemination potential. Establishing a correlation between Ct values and bacterial burden could provide a practical and accessible tool for infection prevention programs.

This prospective observational cohort study will be conducted in the Adult Intensive Care Unit of Hospital Italiano de Buenos Aires. All patients identified through the institutional surveillance program as colonized with CPE will be eligible for inclusion. For each CPE-positive patient, rectal swabs obtained as part of routine surveillance will undergo quantitative culture on selective chromogenic media and molecular testing using real-time PCR targeting carbapenemase genes. Bacterial load will be estimated using colony-forming unit counts and PCR Ct values.

Environmental contamination will be assessed through systematic sampling of high-touch surfaces in the patient's surroundings, including bed linen, bedside furniture, and medical equipment. Environmental isolates will undergo microbiological and molecular characterization. In selected situations, whole genome sequencing or pulsed-field gel electrophoresis will be performed to evaluate genetic relatedness among isolates recovered from patients, environmental samples, and secondary cases.

The primary outcome is the correlation between quantitative bacterial load and PCR Ct values. Secondary outcomes include the extent of environmental contamination associated with different bacterial loads and the occurrence of transmission events involving genetically related strains. Multivariable analyses will evaluate the influence of relevant clinical and epidemiological factors, including length of stay, fecal incontinence, prior antimicrobial exposure, immunosuppression, and other potential confounders.

The study involves minimal risk because all patient samples are obtained within the framework of routine infection control surveillance. Findings from this study may improve the identification of patients with increased transmission potential and support more targeted and efficient infection prevention strategies in critical care settings.

Tipo de estudo

Observacional

Inscrição (Estimado)

60

Contactos e Locais

Esta seção fornece os detalhes de contato para aqueles que conduzem o estudo e informações sobre onde este estudo está sendo realizado.

Contato de estudo

Estude backup de contato

Locais de estudo

    • Buenos Aires F.D.
      • Buenos Aires, Buenos Aires F.D., Argentina, 1199
        • Hospital Italiano de Buenos Aires
        • Contato:
        • Contato:
        • Investigador principal:
          • Maria Ines Staneloni, MD
        • Subinvestigador:
          • Emilio Felipe Huaier Arriazu, MD

Critérios de participação

Os pesquisadores procuram pessoas que se encaixem em uma determinada descrição, chamada de critérios de elegibilidade. Alguns exemplos desses critérios são a condição geral de saúde de uma pessoa ou tratamentos anteriores.

Critérios de elegibilidade

Idades elegíveis para estudo

  • Adulto
  • Adulto mais velho

Aceita Voluntários Saudáveis

Não

Método de amostragem

Amostra Não Probabilística

População do estudo

Adult patients hospitalized in the Adult Intensive Care Unit of Hospital Italiano de Buenos Aires during the study period, with a positive surveillance rectal swab for carbapenemase-producing Enterobacterales detected through the institutional infection control surveillance program.

Descrição

Inclusion Criteria

  • Age 18 years or older.
  • Hospitalized in the Adult Intensive Care Unit of Hospital Italiano de Buenos Aires during the study period.
  • Positive surveillance rectal swab for carbapenemase-producing Enterobacterales.

Exclusion Criteria

-Patients colonized or infected with carbapenemase-producing Enterobacterales who remained in the same room for less than 48 hours.

Plano de estudo

Esta seção fornece detalhes do plano de estudo, incluindo como o estudo é projetado e o que o estudo está medindo.

Como o estudo é projetado?

Detalhes do projeto

Coortes e Intervenções

Grupo / Coorte
CPE-Colonized ICU Patients
Patients admitted to the Adult Intensive Care Unit of Hospital Italiano de Buenos Aires with a positive surveillance rectal swab for carbapenemase-producing Enterobacterales (CPE). Participants will undergo quantitative culture and real-time PCR testing of rectal swabs as part of routine surveillance. Environmental samples will be collected from high-touch surfaces surrounding colonized patients to evaluate environmental contamination and transmission dynamics.

O que o estudo está medindo?

Medidas de resultados primários

Medida de resultado
Descrição da medida
Prazo
Correlation Between PCR Cycle Threshold (Ct) Value and Quantitative Bacterial Load (CFU/swab) in Rectal Surveillance Swabs
Prazo: At baseline (time of positive rectal surveillance swab)
Spearman correlation coefficient between the cycle threshold (Ct) value obtained by real-time PCR (BD MAX™ system) targeting carbapenemase genes and the quantitative bacterial load measured by culture on CHROMagar™ KPC selective medium, expressed as colony-forming units per swab (CFU/swab), from rectal surveillance swabs positive for carbapenemase-producing Enterobacterales.
At baseline (time of positive rectal surveillance swab)

Medidas de resultados secundários

Medida de resultado
Descrição da medida
Prazo
Correlation Between Quantitative Bacterial Load (CFU/swab) in Rectal Swabs and Number of CPE-Positive High-Touch Environmental Surfaces
Prazo: Within 24 hours of rectal swab collection
Spearman correlation coefficient between the quantitative bacterial load of carbapenemase-producing Enterobacterales in rectal surveillance swabs, measured by culture on CHROMagar™ KPC selective medium and expressed as colony-forming units per swab (CFU/swab), and the number of CPE-positive high-touch surfaces out of 5 sampled (bed linen, bedside table, and infusion pump), assessed by quantitative culture on CHROMagar™ KPC contact plates.
Within 24 hours of rectal swab collection
Correlation Between PCR Cycle Threshold (Ct) Value in Rectal Swabs and Number of CPE-Positive High-Touch Environmental Surfaces
Prazo: Within 24 hours of rectal swab collection
Spearman correlation coefficient between the cycle threshold (Ct) value obtained by real-time PCR (BD MAX™ system) targeting carbapenemase genes from rectal surveillance swabs positive for carbapenemase-producing Enterobacterales, and the number of CPE-positive high-touch surfaces out of 5 sampled (bed linen, bedside table, and infusion pump), assessed by quantitative culture on CHROMagar™ KPC contact plates.
Within 24 hours of rectal swab collection
Correlation Between Quantitative Bacterial Load (CFU/swab) in Rectal Swabs and Total Colony-Forming Units Recovered from Environmental Surfaces
Prazo: Within 24 hours of rectal swab collection
Spearman correlation coefficient between the quantitative bacterial load of carbapenemase-producing Enterobacterales in rectal surveillance swabs, measured by culture on CHROMagar™ KPC selective medium and expressed as colony-forming units per swab (CFU/swab), and the total colony-forming units (CFU) recovered across five high-touch surfaces (bed linen, bedside table, and infusion pump) surrounding colonized patients, assessed by quantitative culture on CHROMagar™ KPC contact plates.
Within 24 hours of rectal swab collection
Correlation Between PCR Cycle Threshold (Ct) Value in Rectal Swabs and Total Colony-Forming Units Recovered from Environmental Surfaces
Prazo: Within 24 hours of rectal swab collection
Spearman correlation coefficient between the cycle threshold (Ct) value obtained by real-time PCR (BD MAX™ system) targeting carbapenemase genes from rectal surveillance swabs positive for carbapenemase-producing Enterobacterales, and the total colony-forming units (CFU) recovered across five high-touch surfaces (bed linen, bedside table, and infusion pump) surrounding colonized patients, assessed by quantitative culture on CHROMagar™ KPC contact plates.
Within 24 hours of rectal swab collection
Number of Index Patients with Transmission of at Least One Genetically Related CPE Strain to a Co-Hospitalized Patient
Prazo: Up to 6 months
Number of index patients associated with at least one secondary case carrying a genetically related carbapenemase-producing Enterobacterales strain, confirmed by whole genome sequencing (WGS) and/or pulsed-field gel electrophoresis (PFGE), among patients hospitalized in the same intensive care unit during the study period.
Up to 6 months
Number of Patients Meeting Predefined Criteria for Super-Spreader Classification
Prazo: At baseline (time of CPE detection and environmental sampling)
Number of CPE-colonized patients classified as potential super-spreaders, defined post-hoc as having a cycle threshold (Ct) value below the 25th percentile of the study population and at least 2 positive environmental surfaces with more than 50 colony-forming units (CFU) each, assessed by quantitative culture on CHROMagar™ KPC contact plates.
At baseline (time of CPE detection and environmental sampling)

Colaboradores e Investigadores

É aqui que você encontrará pessoas e organizações envolvidas com este estudo.

Investigadores

  • Investigador principal: Maria Ines Staneloni, MD, Hospital Italiano de Buenos Aires

Publicações e links úteis

A pessoa responsável por inserir informações sobre o estudo fornece voluntariamente essas publicações. Estes podem ser sobre qualquer coisa relacionada ao estudo.

Publicações Gerais

Datas de registro do estudo

Essas datas acompanham o progresso do registro do estudo e os envios de resumo dos resultados para ClinicalTrials.gov. Os registros do estudo e os resultados relatados são revisados ​​pela National Library of Medicine (NLM) para garantir que atendam aos padrões específicos de controle de qualidade antes de serem publicados no site público.

Datas Principais do Estudo

Início do estudo (Estimado)

1 de agosto de 2026

Conclusão Primária (Estimado)

31 de dezembro de 2026

Conclusão do estudo (Estimado)

15 de janeiro de 2027

Datas de inscrição no estudo

Enviado pela primeira vez

9 de junho de 2026

Enviado pela primeira vez que atendeu aos critérios de CQ

29 de junho de 2026

Primeira postagem (Real)

6 de julho de 2026

Atualizações de registro de estudo

Última Atualização Postada (Real)

6 de julho de 2026

Última atualização enviada que atendeu aos critérios de controle de qualidade

29 de junho de 2026

Última verificação

1 de junho de 2026

Mais Informações

Termos relacionados a este estudo

Plano para dados de participantes individuais (IPD)

Planeja compartilhar dados de participantes individuais (IPD)?

SIM

Descrição do plano IPD

Individual participant data underlying the results reported in publications will be available after de-identification. Data may be shared with qualified researchers upon reasonable request to the principal investigator and after approval by the Hospital Italiano de Buenos Aires Ethics Committee, in accordance with institutional policies and applicable regulations regarding data protection and patient confidentiality.

What IPD Will Be Shared? De-identified demographic data Clinical characteristics Rectal swab quantitative culture results PCR cycle threshold (Ct) values Environmental sampling results Molecular characterization and genomic data used in analyses Derived study variables

Prazo de Compartilhamento de IPD

Beginning 6 months after publication and ending 5 years after publication.

Critérios de acesso de compartilhamento IPD

Researchers who provide a methodologically sound proposal may access de-identified participant data for scientific purposes. Requests will be reviewed by the principal investigator and the institutional ethics committee. Data sharing agreements may be required before data release.

Tipo de informação de suporte de compartilhamento de IPD

  • PROTOCOLO DE ESTUDO
  • SEIVA
  • ANALYTIC_CODE
  • CSR

Informações sobre medicamentos e dispositivos, documentos de estudo

Estuda um medicamento regulamentado pela FDA dos EUA

Não

Estuda um produto de dispositivo regulamentado pela FDA dos EUA

Não

Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .

Se inscrever